HOME >> BIOLOGY >> NEWS
Preventing ventilation induced lung injury depends on giving the right number of 'sighs'

Bethesda, MD. (July 25, 2006) Ventilation therapy burst into the public consciousness more than 60 years ago with the "iron lung" and the polio epidemic. Mechanical ventilation has come a long way since then and is used today with patients who cannot breathe on their own because of trauma, lung injuries and chronic lung disease.

But ventilation demands a delicate balance between over inflating and under inflating the lungs, either of which can lead to further injury. Researchers have found that pumping too much air overdistends the lung, leading to ventilator-induced lung injury (VILI).

Doctors currently use small amounts of air (low tidal volume) to protect against VILI. But low tidal volumes can lead to progressive closure of the lungs' air cells, called alveoli, reducing the lung's ability to exchange gases. One way to reverse closure of the alveoli is to periodically give a more robust puff of air, known as deep inflation.

A new study in the online edition of the American Journal of Physiology-Lung Cellular and Molecular Physiology shows that low tidal volume combined with periodic deep inflation provides the best balance between keeping the lung open and preventing VILI in mice. And, using mice, these researchers have shown for the first time that although deep inflation is necessary, it can be overdone.

"There is still a lot of controversy and uncertainty about how best to ventilate the lung," said the study's senior author, Jason HT Bates of the University of Vermont. "One controversy is whether deep inflations, the "sighs" that each of us takes periodically, should ever be given, and if so, how frequently."

Researchers find optimal range

"This study demonstrates that an optimal frequency range of deep inflation delivery exists, at which point the potentially injurious effects of overdistention are outweighed by the protective benefits of maintaining a predominantly open lung," wrote Gilma
'"/>

Contact: Christine Guilfoy
cguilfoy@the-aps.org
301-634-7253
American Physiological Society
25-Jul-2006


Page: 1 2 3 4

Related biology news :

1. Preventing and treating lung cancer -- ESMO explores collaboration to fight cancer on all fronts
2. Preventing cancer without killing cells
3. Preventing obesity in children -- research highlights physical activity levels
4. Preventing graft-versus-host disease disease after bone marrow transplant -- without toxicity
5. Preventing bacterial biofilms could help fight TB
6. Preventing fetal exposure to popular acne drug
7. Preventing a pandemic: Study suggests strategies for containing a flu outbreak
8. Size matters: Preventing large mammal extinction
9. Preventing muscle atrophy
10. Undesirable expatriates: Preventing the spread of invasive animals
11. Preventing SCD1 expression prevents obesity

Post Your Comments:
(Date:10/18/2014)... sample of patients with undiagnosed, suspected genetic conditions, a ... a higher molecular diagnostic yield than traditional molecular diagnostic ... . The study is being released to coincide with ... Exome sequencing, which sequences the protein­coding region of the ... present in a cell or organism), has been rapidly ...
(Date:10/17/2014)... the University of Copenhagen have shown for the first ... of Cystic fibrosis patients, giving them the opportunity to ... chronic infections. , The study also discovered the bacterial ... patients was halted or slowed down by the immune ... the oxygen and helped "suffocate" the bacteria, forcing the ...
(Date:10/16/2014)... Virginia Institute of Marine Science have received a ... to identify the streams and wetlands most vulnerable ... help local governments and citizens conserve these important ... dataset of tidal-marsh observations first gathered by VIMS ... baseline can today,s researchers accurately map the slow ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3
(Date:10/25/2014)... Des Moines, Iowa (PRWEB) October 24, 2014 ... today that Perdue plans to more than double ... in 2015 in geographies supplying its soybean crush ... oil produced from this program will target several ... healthier oil alternatives with good performance. , For ...
(Date:10/25/2014)... 24, 2014 A new way to ... pitfalls of current skin grafting technologies, it also speeds ... The method, outlined in the October issue of STEM ... deep skin injuries that result from severe burns and ... the skin’s regenerative elements. These wounds heal by contraction, ...
(Date:10/25/2014)... 2014 Investor-Edge has initiated coverage ... CYTR ), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX ... Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM ), and ... companies can be accessed at: http://investor-edge.com/register . ... ended on a positive note as the Dow Jones ...
(Date:10/22/2014)... BOSTON , Oct. 22, 2014  Actavis ... specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, today ... to acquire Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., ... for the treatment of diabetic gastroparesis and other GI ... successful Phase 2 trial of relamorelin for the treatment ...
Breaking Biology Technology:DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 2DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 3DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 4New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5
Cached News: